PARIS, France, September 19 /PRNewswire/ -- New data presented today demonstrates that escitalopram is efficacious and well tolerated in the treatment of Obsessive Compulsive Disorder (OCD) with encouraging rates of remission and relapse prevention.(1,2) Presented at a satellite symposium on the occasion of the 19th ECNP Congress in Paris, France, supported by an unrestricted educational grant from Lundbeck, the data suggests that escitalopram may be a promising future treatment option for this common and debilitating condition.
